SCHEMBL31330409

SCHEMBL31330409

COC(=O)c1ccnc(NC2CCOCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.51
NOS1 P29475 8/20 0.48
NOS2 P35228 8/20 0.48
NOS3 P29474 4/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
PRKD1 Q15139 1/20 0.46
PRKD2 Q9BZL6 1/20 0.46
PIP5K1C O60331 1/20 0.46
KDM4E B2RXH2 3/20 0.46
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
ALOX15 P16050 1/20 0.43
PDE10A Q9Y233 1/20 0.43
ALDH1A1 P00352 1/20 0.43
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24473801 0.86 KDM4E (0.48) NOS1NOS2NOS3KDM4EKDM6B
SCHEMBL2299779 0.86 PRMT5 (0.48) NOS1NOS2NOS3PRMT5WDR77
SCHEMBL19356319 0.84 MAPK1 (0.53) NOS1NOS2NOS3PRKD1PRKD2
Hydrochloric Acid SCHEMBL19329186 0.83 MAPK1 (0.52) NOS1NOS2NOS3PRKD1PRKD2
SCHEMBL19329130 0.81 NOS2 (0.61) NOS1NOS2NOS3PRMT5WDR77
SCHEMBL17559284 0.81 NOS2 (0.59) NOS1NOS2NOS3PRMT5WDR77
SCHEMBL23095787 0.79 NOS2 (0.52) NOS1NOS2NOS3PRMT5WDR77
SCHEMBL3713155 0.79 TDP1 (0.41) LRRK2KDM4EALDH1A1OPRK1HDAC3
SCHEMBL30755291 0.78 KDM4E (0.51) LRRK2KDM4EKDM6BKDM5CKDM4C
SCHEMBL27370534 0.78 KDM4E (0.51) LRRK2KDM4EKDM6BKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747242-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland Dac (IE) 2026-05-27 EP disclosed
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-08 US disclosed
WO-2025019715-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TSHR, TRHR LRRK2 228/4885NOS1 1270/4885NOS2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.